Exclusive: ASA calls number of parallel probes ‘significant’ and describes tackling issue as ‘priority’ after it issued ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles to keep ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

The rise of GLP-1 agonist weight loss drugs has prompted the supplement industry to launch a bevy of “natural alternatives” to pharmaceutical compounds like Ozempic and Wegovy. But do they ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch.

Since its online debut late last month, the one-minute ad pitching the company’s legal knockoff of the weight-loss drug Wegovy has stoked the controversy over the high costs of a new generation ...

costs related to Obesity care market development activities and Wegovy launch activities contributed to the increase. Research and development (R&D) costs were up 31% to DKK 13.8 billion.